Achiko’s Rapid Covid-19 Diagnostic Test AptameX™ Receives Product and Registration Approval from Indonesia’s Ministry of Health
Retrieved on:
Wednesday, August 25, 2021
Company, Quarantine, Teman, Government, Indonesia Stock Exchange, Quality of life, IFM, Investment, GLOBE, ACHI, Pharmacy, DNA, SWX, Emergency Government of the Republic of Indonesia, Marketing, COVID-19 testing, Chemistry, Ministry of Health (Saudi Arabia), Republic, Hospital, Ministry, ISIN, CHF, COVID-19, LR, Health status of Asian Americans, CEO, Partnership, Sale, Vaccination, IDX, Technology, Platinum, Pharmaceutical industry, Bank, Animal, Medical device
AptameX, Achikos breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister digital passporting service, Teman Sehat(Health Buddy).
Key Points:
- AptameX, Achikos breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister digital passporting service, Teman Sehat(Health Buddy).
- 53 LR Achiko AG (SWX: ACHI, ISIN CH0522213468) through PT Achiko Medika Indonesia (Achiko, the Company), is pleased to announce that the Ministry of Health of the Republic of Indonesia has granted product and registration approval for its proprietary low-cost, rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service, Teman Sehat (Health Buddy).
- Achikos 50%-subsidiary, PT Achiko Medika Indonesia, and PT Indofarma TBK (Indofarma) have entered into an agreement to manufacture AptameXand have received product registration approval in Indonesia.
- The approval opens the door to the rapid scale-up of production and sale of Achikos AptameXtest kits in Indonesia.